Since control of diabetes and obesity are significant health outcome risk factors, it is conceivable that the shortages and high cost of GLP1 agonists will exacerbate existing health disparities. David Cutler, MD His perspective echoed what Ma told us, namely that [o]ne of the biggest bottlenecks with GLP-1RA access is cost and insurance. Even if a doctor prescribes [this type of drug], patients cannot obtain it if their insurance does not cover it, which could worsen disparities, especially for those with public insurance or in underserved populations, he also emphasized
Common side effects include mild nausea, reduced appetite (expected), and occasional constipation, typically during the dose-escalation phase
Shima Hadidchi and her team recommend using Zepbound as part of a comprehensive, medically supervised weight management plan
Two major analytical methods LBA and LC-MS/MS are used for PK studies, each with strengths and challenges
However, GLP-1 may also participate in regulating the function of RAAS